Boston’s Asimov Takes an Ebola Antibody Order Payable in Cell Banks

Boston’s Asimov and Emergent BioSolutions are developing research cell banks for two Ebola antibody candidates, an early step toward making material for study.

Share
SiliconSnark robot receives two research cell banks at a Boston lab overlooking the Longfellow Bridge.

In Boston biotech, “going to the bank” can mean a meeting with a lender or a trip down the hall wearing insulated gloves. This week I’ll take the second meeting. Somewhere in the journey from an idea for an antibody to a medicine somebody can actually receive, a team has to take delivery of living cells, put them away, and be reasonably confident it can get back to work when it opens the freezer.

This week, Boston-based Asimov and Maryland-based Emergent BioSolutions announced two cell line development campaigns, one for each of two monoclonal antibodies targeting Ebola. Each campaign runs through shipment of a research cell bank. Emergent brings experience developing and manufacturing medical countermeasures. Asimov brings its CHO Edge system and the people who will do the work. The announcement gives no contract price, shipment date or clinical results. It does give us a deliverable, which puts it several lengths ahead of the average press release containing the word “partnership.”

What exactly arrives in the box?

An antibody is a protein. A monoclonal antibody candidate has a particular molecular identity, and researchers need a dependable supply of material with that identity to study it. Knowing which antibody you want leaves a fairly large purchasing question open. Who is going to make the stuff, and what will the next team start from when it needs more?

A cell line is a population of cells that researchers can keep growing. Here, the cells are meant to produce the antibody. A research bank preserves portions of that population so that future work can begin from a common starting point. Think about the difference between handing a colleague a slice of sourdough and handing over some starter. Now imagine a workplace where somebody takes minutes at the starter handoff. For this application, I find myself firmly on the side of the minutes.

The companies describe the intended banks as “high-titer.” In plain English, they want the cells to produce a relatively high concentration of antibody. Concentration matters because a research team needs actual material to examine, and a productive line makes that job easier. The partners give no numerical target or measured result for either candidate. Even an excellent concentration figure would answer a production question. Whether an antibody helps someone sick with Ebola is a different question, requiring its own evidence.

The software has a shipping department

Asimov calls its platform AI-native. I used to do predictive analytics, so my professional instinct is to ask what happens after the prediction. Here there is a satisfying answer. The company pairs its Kernel design software with a system built around Chinese hamster ovary cells, commonly shortened to CHO. The software contributes to design decisions. Living cells have to produce the material. At the far end of the agreement, somebody at Emergent should have something tangible to receive.

That division of labor gives outsiders a decent way to judge the AI pitch. A screenshot can show that a design exists. A bank that another team can use has survived more encounters with reality, including the unusually rigorous peer review administered by a shipping address. We still don’t know how much time the software will save on these projects, how its choices will compare with other approaches, or what each campaign will cost. Those would be interesting results to report when there are results.

Two candidates make for honest arithmetic

There’s a modest virtue in the number two. It tells us the scale of the commitment and preserves a distinction that gets lost when the phrase “Ebola breakthrough” starts warming up in the headline bullpen. The partners have agreed to work on two candidates. They haven’t said the two will be administered together, established how either will perform in patients, or announced doses available for an emergency. A freezer full of research material and a public health stockpile occupy very different places on a calendar.

For someone outside Massachusetts, that calendar is the reason to care. Preparedness involves paying attention to decisions whose value may only become obvious much later. If scientists want to compare candidates, they need enough material to make the comparison meaningful. If they decide to concentrate on one, the people doing the next round of work benefit from knowing where their starting material came from. An agreed handoff makes those future choices easier to imagine and, eventually, easier to make.

A Boston export with the homework attached

Asimov was founded by bioengineers from MIT and Boston University and is headquartered in Boston. The useful local detail is what those engineers have built a business around. A company elsewhere can buy a piece of development work with a defined endpoint. You can draw a straight line from university engineering talent to a customer’s receiving dock without detouring through a panel discussion about the innovation economy. Somewhere along the Red Line, a moderator has just gained forty minutes.

This is familiar territory for a region where Azenta makes a business of keeping samples usable and Bluefin built software for the operational headaches of clinical trials. The drama tends to accrue farther downstream, when a developer like Cambridge’s Apnimed reaches FDA review. Much earlier, somebody has to produce an object another person can trust enough to spend the next research dollar on it.

My verdict is a serious manufacturing bet, sensibly sized. Give the partners credit for saying where their work together is supposed to end. When a bank ships, the interesting follow-up will be what Emergent can learn with the material it receives. Until then, two concrete assignments and a place to send the results are quite enough news for one Tuesday. Boston can save the ballroom deposit.